BioInvent International AB (LTS:0H22)
kr 45.15 0 (0%) Market Cap: 2.84 Bil Enterprise Value: 1.80 Bil PE Ratio: 0 PB Ratio: 2.59 GF Score: 51/100

Q4 2020 BioInvent International AB Earnings Call Transcript

Feb 23, 2021 / 02:00PM GMT
Release Date Price: kr51 (+2.72%)
Operator

Welcome to the BioInvent Q4 reports 2020. Today I'm pleased to present CEO, Martin Welschof; and CFO, Stefan Ericsson. (Operator Instructions)

Speakers, please begin.

Martin Welschof
BioInvent International AB - CEO

Yes. Thank you very much for the introduction, and welcome, everybody, to our audiocast for the Q4 2020. The next slide, please.

On the next slide, you see our forward-looking statements since we are listed in Stockholm.

And then on slide number three, you will see a very brief snapshot of the company. So just to remind everybody, we are an antibody discovery and target discovery company, and we are focusing clearly on cancer immunotherapy. And there specifically, we are focusing on overcoming tumor resistance.

We have a lead program, BI-1206. This is currently in a Phase I/II clinical trial for non-Hodgkin lymphoma, and also in a Phase I/II trial for solid tumors, and I'll come back to that later in a little bit more detail.

And then, we have two additional programs. So currently, we have four

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot